Parkinson’s UK Drug Discovery Manager joins DTR advisory board
Posted: 28 September 2017 | Steve Bremer (Drug Target Review) | No comments yet
Drug Target Review welcomes Janusz Kulagowski to its advisory board …
Janusz Kulagowski, Drug Discovery Manager at Parkinson’s UK, has joined Drug Target Review’s editorial advisory board.
Prior to taking on his current role, Jan spent 20 years working in neuroscience at Merck & Co. He also bring expertise of contract research from his position at Argenta Discovery.
Parkinson’s UK is a support and research charity leading the work to find a cure, and it believes that it is “closer than ever” to this aim. Since 1969, the charity has invested over £80m in groundbreaking research.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Related topics
Drug Discovery, Neurosciences, Research & Development
Related conditions
Parkinson's disease
Related organisations
Parkinson's UK
Related people
Janusz Kulagowski
